Margins in Breast-Conserving Surgery After Neoadjuvant Therapy
Optimal margin width for breast-conserving therapy (BCT) after neoadjuvant chemotherapy (NAC) is unknown. We sought to determine the impact of margin width on local recurrence and survival after NAC and BCT.
Patients treated with NAC and BCT for stage I–III breast cancer from 2002 to 2014 were identified. Multivariate Cox regression was performed to determine the relationship between margin width and local recurrence free-survival (LRFS), disease-free survival (DFS), and overall survival (OS).
A total of 382 patients were included. Median age was 51 years [range 22–79], median tumor size 3.0 cm [range 0.6–11.0], and receptor subtypes included 144 (37.7%) HR−/HER2−, 47 (12.3%) HR−/HER2+, 118 (30.9%) HR+/HER2−, and 70 (18.3%) HR+/HER2+. Breast pathologic complete response (pCR) was achieved in 105 (27.5%) patients. Final margin status was positive in 8 (2.1%) patients, ≤ 1 mm in 65 (17.0%), 1.1–2 mm in 30 (7.9%), and > 2 mm in 174 (45.5%). The 5-year LRFS was 96.3% (95% CI 94.0–98.6), DFS was 85.5% (95% CI 81.8–90.7), and OS was 90.8% (95% CI 87.4–94.2). There was no difference in LRFS, DFS, or OS for margins ≤ 2 versus > 2 mm, and no difference in DFS or OS for margins ≤ 1 versus > 1 mm. HR+ subtype (p = 0.04) and pCR (p = 0.03) were correlated with favorable DFS and node negativity (p < 0.001) with favorable DFS and OS.
In this cohort treated with NAC and BCT, there was no association between margin width and LRFS, DFS, or OS. Although further studies are needed, the excellent long-term outcomes demonstrated in patients with close (≤ 2 mm) margins following NAC suggest that a margin of “no-ink-on-tumor” may be acceptable in appropriately selected patients.
The authors have no disclosures to declare.
- 11.R Development Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria (2008). http://www.R-project.org. ISBN 3-900051-07-0.
- 13.Mukhtar RA, Yau C, Rosen M, Tandon VJ, I-SPY 1 TRIAL and ACRIN 6657 Investigators, Hylton N, Esserman LJ. Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Ann Surg Oncol. 2013;20:3823–30.CrossRefGoogle Scholar
- 16.Boughey JC, McCall LM, Ballman KV et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann Surg 2014;260:608–14 (discussion 614–6).CrossRefGoogle Scholar